TRPV4 and COVID-19: Although studies have proposed TRPV4 in SARS-CoV-2 infection, and targeted inhibition of TRPV4 is a candidate therapeutic approach against COVID-19,47,48 our results indicate that acute exposure, but not prolonged exposure, to S-RBD leads to increased TRPV4 activity.